Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Dermatologic 1

Conditions

Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1

Interventions

pembrolizumab 29Nivolumab 29Specimen Handling 24Ipilimumab 19Magnetic Resonance Spectroscopy 17Biopsy 11CTLA-4 Antigen 9Opdualag 8Cyclophosphamide 8relatlimab 6Paclitaxel 6trametinib 5fludarabine 5cemiplimab 5Carboplatin 5fludarabine phosphate 4dabrafenib 4binimetinib 4avelumab 4HhAntag691 4lifileucel 3capivasertib 3atezolizumab 3aldesleukin 3X-Rays 3Temozolomide 3Taxes 3Surgical Procedures, Operative 3Standard of Care 3Pemetrexed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
sodium-iodide symporter × Dermatologic × 30 days × Clear all
NCT03017820 2026-05-28

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic

Phase 1 Recruiting
99 enrolled
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡